

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q4 12-13	Q4 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Domestic	7,411	6,444	15.0%	29868	24542	21.7%
Formulations	5,708	4,989	14.4%	23,232	18,950	22.6%
API	138	147	-6.1%	522	438	19.2%
Wellness	1,084	857	26.4%	4,100	3,446	19.0%
Animal Health & Others	481	451	6.8%	2,014	1,708	17.9%
Exports	7,429	6,209	19.7%	27,910	23,031	21.2%
Formulations	6,600	5,486	20.3%	24,885	20,298	22.6%
US	3,882	3,533	9.9%	15,068	12,431	21.2%
Europe	961	706	36.0%	3,697	2,983	23.9%
Japan	141	136	3.4%	603	522	15.5%
Brazil	586	556	5.5%	2,384	2,473	-3.6%
Emerging Mkts & Others	1,030	555	85.6%	3,134	1,889	65.9%
API	721	597	20.8%	2,577	2,416	6.7%
Animal Health & Others	108	125	-13.9%	448	316	41.6%
JVs	1,153	1,140	1.1%	5,070	4,234	19.8%
Total	15,993	13,793	15.9%	62,848	51,807	21.3%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q4 12-13	Q4 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Other Operating Income	461	536	-14.0%	2,027	1,733	17.0%
Dossier Fees	0	18	-100.0%	2	513	-99.6%
Royalty Income	304	143	112.6%	600	356	68.5%
Net Gain on foreign currency transactions and translation (Refer Note below)	-93	0		500	0	
Others	250	375	-33.4%	925	864	7.0%

Note : Apart from this loss, there was a net loss of Rs. 97 Mio. in Q4 12-13 on hedging and on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods. Thus, on aggregate level, there was a loss of Rs. 189 Mio. on operating transactions (above EBIDTA line) in Q4 12-13 vs loss of Rs. 235 Mio. in Q4 11-12. See details below for more clarity.

Rs. Mio.	Q4 12-13	Q4 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Other Income	87	154	-43.3%	370	509	-27.3%
Interest & Dividend income	103	86	19.9%	321	313	2.7%
Profit on sale of investments	9	1	896.6%	23	59	-61.0%
Profit on sale of assets	0	-8	100.0%	0	1	-100.0%
Others	-25	75	-133.1%	26	137	-81.0%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q4 12-13	Q4 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
A. On operating transactions (above EBIDTA line)	189	235	-19.5%	174	109	60.4%
a. Included in other income	93	0		-500	0	
b. Included in cost of goods	97	265	-63.6%	675	-36	1986.6%
c. Included in other expenses	0	-30	99.6%	0	144	-100.1%
B. On Foreign Currency Borrowings (part of interest cost)	-12	7	-271.1%	425	776	-45.2%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	177	242	-26.8%	599	884	-32.3%

Details of R&D Expenses

Rs. Mio.	Q4 12-13	Q4 11-12	% Gr y-y	YTD 12-13	YTD 11-12	% Gr y-y
Total R&D Expenses	1,261	891	42%	4,705	3,608	30%

Consolidated Capex for Apr 12-Mar 13

Rs. 6880
Mio.

R&D capex included in above for Apr 12-Mar 13 :

Rs. 495
Mio.